This cross-sectional study investigates the relationship between serum IGF-1 and IGF-1Ec (E-peptide/MGF) levels and tumor burden in patients with solid tumors. By analyzing serum samples using ELISA and correlating them with clinical data such as tumor stage, size, metastasis, and lymph node involvement, the study aims to explore whether these biomarkers-particularly IGF-1Ec and the IGF-1Ec/IGF-1 ratio-can reflect tumor progression and serve as potential prognostic indicators.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years
* Histologically confirmed diagnosis of a solid tumor
* Clinically stable condition, prior to chemotherapy or during standard follow-up
* Ability to provide informed consent
Exclusion Criteria:
* Hematological malignancies (e.g., leukemia, lymphoma)
* Acute or chronic liver or kidney failure
* Current use (within 1 month) of corticosteroids, growth hormone, or medications affecting IGF-1 levels
* Pregnancy or lactation
* Coagulopathy or severe anemia preventing safe venipuncture
Primary outcome measure(s)
IGF-1 and IGF-1Ec levels — From enrollment to 6 month Blood values
Trial sites (1)
Facility
City
Region
Status
Çanakkale Onsekiz Mart University
Çanakkale
Turkey (Türkiye)
More Çanakkale Onsekiz Mart University trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.